Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer.
Adult
Aged
Antineoplastic Agents, Immunological
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Diagnosis, Differential
Female
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Mutation
Mutation Rate
Neoplasm Staging
Prognosis
Retinoblastoma Binding Proteins
/ genetics
Small Cell Lung Carcinoma
/ drug therapy
Survival Analysis
Treatment Outcome
Ubiquitin-Protein Ligases
/ genetics
genomics
immunotherapy
non small cell lung cancer
response
retinoblastoma
small cell lung cancer
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
09
10
2018
revised:
07
01
2019
accepted:
16
01
2019
pubmed:
19
2
2019
medline:
8
5
2020
entrez:
19
2
2019
Statut:
ppublish
Résumé
The retinoblastoma gene (RB1) encodes the retinoblastoma (RB) pocket protein that plays an important role in cell cycle progression. Here we determine the frequency and prognostic significance of RB1 mutation in non small cell lung cancer (NSCLC), restricting inclusion to Stage III and IV patients with linked genomic and clinical data. The primary outcome was median overall survival (OS). We identified RB1 mutation in 8.2% of NSCLC patients. The median OS for wild-type (wt) RB1 was 28.3 months vs 8.3 months for mutant RB1 (Hazard Ratio = 2.59, P = 0.002). Of special interest, RB1 mutation also correlated with lack of response to immunotherapy. Our study focused on RB1 mutation in locally advanced and advanced non small cell lung cancer to better facilitate comparisons with small cell lung cancer (SCLC). In our SCLC cohort, RB1 mutation was identified in 75% of patients and wt RB1 was associated with significantly shorter OS (P = 0.002). The different outcomes of RB1 mutation observed among lung cancer subtypes suggest a more complicated mechanism than simple regulation of cell cycle or response to chemotherapy.
Identifiants
pubmed: 30773851
doi: 10.1002/cam4.2023
pmc: PMC6488103
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
RB1 protein, human
0
Retinoblastoma Binding Proteins
0
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1459-1466Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Ann Oncol. 2016 Apr;27(4):642-7
pubmed: 26802149
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Cancer Res. 1996 Aug 1;56(15):3415-20
pubmed: 8758904
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Mol Cell. 2007 Nov 9;28(3):371-85
pubmed: 17996702
Nat Commun. 2015 Mar 11;6:6377
pubmed: 25758528
Hepatology. 2014 Oct;60(4):1231-40
pubmed: 24824777
Clin Cancer Res. 2012 Sep 15;18(18):5110-22
pubmed: 22811582
Clin Cancer Res. 1999 Apr;5(4):791-800
pubmed: 10213214
Adv Cancer Res. 2014;121:147-182
pubmed: 24889531
J Clin Oncol. 2017 Jan 10;35(2):243-252
pubmed: 28056194
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Urol Oncol. 2010 May-Jun;28(3):285-9
pubmed: 18976938
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Cancer Biol Ther. 2016 Nov;17(11):1197-1205
pubmed: 27645778
Nat Genet. 2012 Oct;44(10):1111-6
pubmed: 22941189
Cancer Res. 1995 Feb 1;55(3):505-9
pubmed: 7834618
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4
pubmed: 8633069
Cancer Med. 2019 Apr;8(4):1459-1466
pubmed: 30773851
Sci Transl Med. 2015 Apr 15;7(283):283ra53
pubmed: 25877891
J Natl Cancer Inst. 2000 Dec 20;92(24):2037-9
pubmed: 11121467
J Natl Cancer Inst. 2008 Dec 17;100(24):1771-9
pubmed: 19066271
Nat Genet. 2012 Oct;44(10):1104-10
pubmed: 22941188
Cell Cycle. 2015;14(24):3812-9
pubmed: 25714546
Clin Cancer Res. 2016 Jul 1;22(13):3148-56
pubmed: 26861459
Nat Rev Cancer. 2008 Sep;8(9):714-24
pubmed: 19143056
Clin Cancer Res. 2015 Jun 1;21(11):2613-23
pubmed: 25294902
N Engl J Med. 1976 Nov 11;295(20):1120-3
pubmed: 980006
J Oncol. 2012;2012:957437
pubmed: 22619677
J Virol Methods. 2014 Sep;206:12-8
pubmed: 24880067
Oncotarget. 2017 Aug 28;8(43):73745-73756
pubmed: 29088741
J Clin Oncol. 2016 Oct 20;34(30):3638-3647
pubmed: 27480147
Cancer. 2007 Mar 15;109(6):1097-105
pubmed: 17311305
Lung Cancer. 2001 Nov;34(2):207-18
pubmed: 11679179
Nat Med. 2012 Mar 06;18(3):349-51
pubmed: 22395697
Cell Cycle. 2015;14(1):109-22
pubmed: 25602521